Document:

Exhibit 10.23

 

Share Transfer Agreement

 

Of

 

Jinhua Kandi New Energy Vehicles Co., Ltd

 

Transferor (Party A): Hu Xiaoming

Transferee (Party B): Zhejiang Kandi Technologies
Group Co., Ltd.

 

Approval by the resolutions
of shareholders’ meeting of Jinhua Kandi New Energy Vehicles Co., Ltd, Party A and Party B reached the following agreement on the share
transfer of Jinhua New Energy Vehicles Co., Ltd:

 

1. Amount of the transferred share and its price:
Party A is willing to sell 50% of the equity interest of Kandi New Energy Vehicles Co., Ltd. (the subscribed capital contribution is RMB
18 million) to Party B at a price of RMB 18 million, and Party B is willing to transfer the above equity interest at such price.

 

2. After the share transfer, the corresponding
rights and obligations of Party A, as a shareholder, in Kandi New Energy Vehicles Co., Ltd shall be assumed by Party B.

 

3. Party A guarantees that he has the full right
to dispose of the transferred equity interest, and there is no reason for the share to be pledged or frozen. Party A must cooperate with
Party B and Kandi New Energy Vehicles Co., Ltd. to go through the transfer and modification procedures of the equity interest of this
target with the registration authority in accordance with applicable law.

 

4. Liability for breach of contract and settlement
of disputes: If any party to the agreement violates this agreement, and causes losses to the other party, the breaching party shall be
liable and compensate for the economic losses caused to the other party.

 

5. In case of any dispute arising from this
agreement, both parties shall resolve it through negotiation. If the negotiation fails, they shall file a lawsuit in the people’s
court according to relevant law.

 

6. This agreement is made in triplicate,
with each party holding one copy. It shall take effect after being signed (sealed) by both parties.

 

Signature (seal) of the transfer (Party A):

 

Signature (seal) of the transferee (Party B):

 

March 7, 2022Exhibit
10.28

 

DEBT
CONVERSION AGREEMENT

 

THIS
DEBT CONVERSION AGREEMENT (this “Agreement”) is made and entered into as of October 8, 2021 by and between Bone Biologics
Corporation, a Delaware corporation (the “Company”), and Hankey Capital, LLC (“Purchaser”).

 

RECITALS

 

A.
Purchaser has made advances to the Company in the aggregate amount of $12,767,894 (the “Advances”) evidenced by convertible
notes as well as pursuant to credit facilities. To secure the obligations of the Company under the Advances, the Company issued to Purchaser
shares of its Common Stock (the “Collateral Shares”).

 

B.
The Company is engaging in an underwritten public offering of shares of its Common Stock and warrants to purchase Common Stock (the “Public
Offering”). In connection with the Public Offering, the Company will effect a reverse split of one-to-2.5 (the “Reverse
Split”).

 

C.
On the terms and subject to the conditions of this Agreement, Purchaser desires to convert the Advances, together with accrued interest
thereon in the amount of $2,054,039 (the “Accrued Interest”), for shares of the Common Stock of the Company at a conversion
rate of $2.50 per share on a post Reverse Split basis.

 

NOW,
THEREFORE, with reference to the foregoing facts, the Company and the Purchaser agree as follows:

 

AGREEMENT

 

1.
Conversion of Advances and Accrued Interest and Cancellation of Collateral Shares. The Company hereby agrees to issue to Purchaser
an aggregate of 5,928,774 shares (the “Shares”) of Common Stock of the Company, and the Purchaser hereby agrees to
convert the Advances and Accrued Interest into the Shares. The number of Shares has been determined based upon dividing the outstanding
Advances and Accrued Interest by $2.50, which is the applicable conversion price post Reverse Spit. The Company agrees to instruct its
transfer agent to issue the Shares to Purchaser promptly upon closing of the Public Offering. It is understood that any additional accrued
interest on the Advances shall be paid by the Company in cash at the closing of the Public Offering. Additionally, Purchaser agrees to
cancel and return to the Treasury of the Company an aggregate of 9,361,702 shares of Common Stock on a post Stock Split basis representing
all of the Collateral Shares. The conversion of the Advances and Accrued Interest and cancellation of the Collateral Shares shall occur
concurrently with the closing of the Public Offering and is conditioned thereon.

 

2.
Representations and Warranties of the Purchaser. Purchaser hereby represents and warrants to, and agrees with, the Company as
follows:

 

2.1
Purchaser understands that: (a) the Shares are not registered under the Securities Act of 1933, as amended (the “Securities
Act”), or any state securities laws; (b) the issuance and sale of the Shares is intended to be exempt from registration under
the Securities Act, by virtue of Section 4(2) thereof and the provisions of Regulation D promulgated thereunder, based, in part, upon
the representations, warranties and agreements of the Purchaser contained in this Agreement.

 

    	 

    	 

    

 

2.2
Purchaser is acquiring the Shares solely for the Purchaser’s own account for investment and not with a view to resale or distribution
thereof, in whole or in part.

 

2.3
Purchaser must bear the substantial economic risks of the investment in the Shares indefinitely, because none of the Shares may be sold,
assigned, transferred, hypothecated or otherwise encumbered or disposed of unless subsequently registered under the Securities Act and
applicable state securities laws or any exemption from such registration is available. Legends shall be placed on the Shares to the effect
that they have not been registered under the Securities Act or applicable state securities laws. In addition, appropriate notations thereof
will be made in the Company’s books, and stop transfer instructions will be placed with the transfer agent of the Shares.

 

2.4
Purchaser has adequate means of providing for such Purchaser’s current financial needs and foreseeable contingencies and has no
need for liquidity of the investment in the Shares for an indefinite period of time.

 

2.5
PURCHASER UNDERSTANDS THAT AN INVESTMENT IN THE SHARES INVOLVES A HIGH DEGREE OF RISK.

 

2.6
Purchaser is an “accredited investor” under Regulation D under the Securities Act.

 

3.
Miscellaneous

 

3.1
This Agreement constitutes the entire agreement between Purchaser and the Company with respect to the subject matter hereof and supersedes
all prior oral or written agreements and understandings, if any, relating to the subject matter hereof. The terms and provisions of this
Agreement may be waived, or consent for the departure therefrom granted, only by a written document executed by the party entitled to
the benefits of such terms or provisions.

 

3.2
Purchaser’s representations and warranties made in this Agreement shall survive the execution and delivery hereof and delivery
of the Shares.

 

3.3
This Agreement may be executed in one or more counterparts each of which shall be deemed an original, but all of which shall together
constitute one and the same instrument.

 

3.4
Each provision of this Agreement shall be considered separable and if for any reason any provision or provisions hereof are determined
to be invalid or contrary to applicable law such invalidity or illegality shall not impair the operation of or affect the remaining portions
of this Agreement.

 

3.5
This Agreement shall be governed by and construed in accordance with the laws of the State of Delaware relating to contracts entered
into and to be performed wholly within such State.

 

3.6
Paragraph titles are for descriptive purposes only and shall not control or alter the meaning of this Agreement as set forth in the text.

 

    	- 2 -

    	 

    

 

	 	Bone
    Biologics Corporation
	 	 	 
	 	By:	 
	 	Name:	Jeffrey
    Frelick 
	 	Its:	Chief
    Executive Officer
	 	 	 
	 	PURCHASER:
	 	Hankey
    Capital, LLC
	 	 
	 	 	
	 	By:	Don
    Hankey, Manager

 

    	- 3 -Exhibit
10.30

 

 

 

SUPPLY
AND DEVELOPMENT SUPPORT AGREEMENT

 

by
and between

 

BONE
BIOLOGICS CORPORATION

 

and

 

MUSCULOSKELETAL
TRANSPLANT FOUNDATION, INC.

 

 

 

 

Dated
as of March 3, 2022

 

    	 

    	 

    

 

Supply
AND Development support agreement

 

THIS
SUPPLY and DEVELOPMENT SUPPORT AGREEMENT (this “Agreement”), dated as of the 3rd day of March,
2022 (“Effective Date”), is made and entered into by and between BONE BIOLOGICS CORPORATION, a corporation
organized under the laws of the State of Delaware, and having a principal place of business at 2 Burlington Woods Drive, Suite 100, Burlington,
Massachusetts 01803 (“BBC”), and MUSCULOSKELETAL TRANSPLANT FOUNDATION, INC., a District of Columbia
non-profit corporation, with its principal place of business at 125 May Street, Suite 300, Edison, New Jersey 08837 (“MTF”).

 

W I T N E S S E T H:

 

WHEREAS,
MTF processes DBM demineralized bone matrix (“DBM”) tissue for human implantation and is the owner of intellectual
property and other tangible and intangible rights relating thereto; and

 

WHEREAS,
BBC has expertise in the field of regenerative medicine orthobiologics, including without limitation the application and uses of demineralized
bone matrix in patients; and

 

WHEREAS,
the parties hereto desire that (i) BBC will undertake all pre-manufacturing and post-manufacturing testing and other activities to
support the safe and effective implant of its proprietary Nell-1 technology (“Nell-1”) into human patients;
(ii) MTF will be the exclusive supplier of DBM to BBC for use with Nell-1; and (iii) MTF will provide reasonable development support
to BBC, as detailed herein, for the development of Nell-1 with DBM as a carrier.

 

NOW,
THEREFORE, in consideration of the mutual promises contained herein, BBC and MTF agree as follows:

 

ARTICLE
I 

DEFINITIONS

 

Section
1.1 Business Day. Business Day shall mean any day other than a Saturday, Sunday or a day on which banking institutions in
the State of New Jersey are authorized or obligated by law to close.

 

Section
1.2 BBC Designated Warehouse. BBC Designated Warehouse shall mean the warehouse location within MTF’s facilities (initially
at 1175 Mid-Valley Drive, Olyphant, Pennsylvania), dedicated for storage of BBC Inventory in accordance with the terms and provisions
of this Agreement.

 

Section
1.3 BBC Inventory. BBC Inventory shall mean DBM which is purchased by BBC for use with Nell-1, and delivered to the BBC Designated
Warehouse hereunder.

 

Section
1.4 BBC Order. BBC Order shall mean, subject to section 3.3(b), a purchase order for any BBC Inventory to be delivered to
the BBC Designated Warehouse placed by BBC with MTF.

 

    	 

    	 

    

 

Section
1.5 DBM IP. DBM IP shall mean the technology underlying the DBM, including without limitation, all trade secrets, know-how
and any patented or patentable or otherwise protectable intellectual property relating to the DBM, including MTF’s Intellectual
Property covering or related to DBM including without limitation, U.S. Patent Numbers US 6,030,635, US 6,437,018, RE 38,522 (Re-Issue
of US 6,437,018), RE 39,587 (Re-Issue of US RE 38,522 and US 6,4370,18), US 7,019,192, US 6,911,212, US 7,045,141, and any divisional,
continuation, or continuation-in-part application, and/or any foreign patent application and/or Letters Patent, and/or the equivalent
thereof issuing thereon, and/or reissue, reexamination or extension thereof, including any improvements, modifications or enhancements
thereto.

 

Section
1.6 Field. Field shall be defined to mean only those approved indications for use established by the applicable Regulatory
Authorities in the Territory, including without limitation, those indications for use established by the U.S. Food and Drug Administration
pursuant to the Premarket Approval Application (PMA) Clearance, attached hereto as Exhibit A.

 

Section
1.7 Intellectual Property. Intellectual Property shall mean any and all patents, patent applications, inventions, copyrights,
trademarks, trade secrets, know-how, and all other inventions, discoveries and ideas, computer programs, software, firmware and related
documentation, know-how and any other technology, trade secrets and confidential information.

 

Section
1.8 MTF Service Fees. MTF Service Fees shall mean the transfer prices charged by MTF to BBC for purchase of DBM. The MTF Service
Fees for DBM shall be mutually determined by the parties after the Effective Date and shall be memorialized in Exhibit B
attached hereto. The MTF Service Fees may be increased by MTF for the immediately following calendar year only on written notice by MTF
to BBC by October 1 of any year during the Term; provided, however, that any such annual increase in the MTF Service Fees shall not exceed
the percentage change in the Consumer Price Index for medical care services (U.S. City Average, all urban consumers), published by the
U.S. Bureau of Labor Statistics or its successors for the immediately preceding year, absent the mutual agreement of MTF and BBC otherwise.

 

Section
1.9 Regulatory Authority. Regulatory Authority shall mean any federal, national, international, state or local regulatory
authority, regulatory agency or other governmental body or entity in any country with authority over the research, development, testing,
manufacture, use, storage, importation, promotion, marketing, pricing or sale of a pharmaceutical product in such country, including
without limitation, the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).

 

Section
1.10 Term. Term shall mean the Initial Term and all Renewal Periods.

 

Section
1.11 Term Year. Term Year shall mean the twelve-month period commencing on the Effective Date or any anniversary thereof and
terminating on the anniversary of the date immediately preceding the Effective Date or any anniversary thereof, as the case may be.

 

Section
1.12 Territory. Territory shall mean worldwide.

 

    	3

    	 

    

 

ARTICLE
II

SUPPLY
OF PRODUCTS 

 

Section
2.1 Sole Supplier; Exclusivity; Non-Competition. Subject to the terms and conditions of this Agreement:

 

(a)
MTF shall be the sole processor, manufacturer and supplier of DBM for use with Nell-1 by BBC. MTF may provide DBM under an existing or
new trade name, in MTF’s sole discretion; provided, however, that such branded DBM shall have the same formulation as any unbranded
DBM supplied to BBC hereunder. Notwithstanding the foregoing, however, if MTF is unable to supply BBC’s reasonably forecasted demand
for DBM, then BBC shall have the right to source demineralized bone matrix from third-party suppliers thereof. BBC shall have the exclusive
right to use, sell and/or distribute DBM only in conjunction with Nell-1, and during the Term, MTF shall not supply DBM to any third
party that MTF knows or should reasonably know intends to use such supplied DBM in conjunction with Nell-1; and

 

(b)
BBC shall not market, offer for sale, sell or transfer any DBM-competitive demineralized bone matrix product, nor shall BBC assist any
third party to market, offer for sale, sell or transfer any DBM-competitive demineralized bone matrix product within the Territory and
the Field. Whether a product is a competitive product shall be reasonably determined by MTF in good faith, which determination shall
take into consideration the overlapping indications of such product with DBM.

 

Section
2.2 BBC Orders; Payment.

 

(a)
All BBC Orders for DBM from MTF shall be on such forms as are from time to time prescribed by MTF, and BBC shall not submit any order
that contains any terms or conditions at variance with the terms of this Agreement or in any manner supplemental thereto. All BBC Orders
shall be subject to acceptance and confirmation in writing by a duly authorized representative of MTF within thirty (30) days of MTF’s
receipt of such BBC Order. Under no circumstances shall MTF bear any such freight, shipping or related charges incurred to deliver DBM
from the BBC Designated Warehouse (all of which shall be the responsibility of BBC).

 

(b)
All invoices shall be issued by MTF upon delivery of Product to BBC or its designee, and such invoices shall be due and payable NET thirty
(30) days from the date of BBC’s receipt of the applicable invoice from MTF. If payment is not received within the prescribed period,
then (i) MTF shall notify BBC of such failure, and (ii) interest shall accrue on any unpaid balance from the date of the invoice at the
rate of 1.5% per month (18% per annum), but, in no event at a rate greater than the maximum rate permitted by applicable law.

 

(c)
Return of DBM shall be permitted in accordance with MTF’s Return Policy, attached hereto at Exhibit C

 

Section
2.3 Sales and Marketing Literature. Catalogues, brochures, websites, sales training material and any other product literature
relating to DBM (the “Literature”) shall be prepared by BBC, at BBC’s expense. Prior to the finalization
or use of any Literature, MTF shall be given a reasonable amount of time not to exceed fourteen (14) days to review and comment on any
such Literature, particularly insofar as the content of such Literature may relate to regulatory and/or product liability issues or utilize
any Intellectual Property of MTF or certain statements about MTF or DBM. MTX’s failure to provide its comments on any such Literature
within the fourteen (14) day review period shall be deemed MTX’s approval thereof. BBC shall incorporate MTF modifications to the
Literature which are mandated by regulations and/or product liability law or relate to any Intellectual Property of MTF or correct any
factual inaccuracies. In addition, BBC shall use its reasonable efforts to incorporate any other reasonable changes in such Literature
suggested by MTF on a timely basis. BBC shall be responsible for the costs of reprints of the Literature. DBM shall be marketed and distributed
pursuant to this Agreement under MTF’s tradename and trade dress and any Literature shall reference DBM accordingly.

 

    	4

    	 

    

 

ARTICLE
III

PRODUCTION 

 

Section
3.1 Testing; Development; Delivery

 

(a)
BBC acknowledges and agrees that use of DBM as a carrier with Nell-1 is subject to further development. BBC understands and acknowledges
that prior to distribution of Nell-1 with DBM as a carrier, certain studies and testing are required and which BBC shall, at its own
cost and expense, undertake. BBC understands that such testing shall be pre- and post-manufacturing of Nell-1 or DBM and that additional
testing may be required from time-to-time during the Term, as mandated by law, regulation or guidance documents or in MTF’s reasonable
discretion. BBC shall be solely responsible for undertaking and paying all costs associated with pre- and post-manufacturing testing
which may include, without limitation, clinical studies, validations and verifications relating to stability, packaging, sterility, process
and other internal manufacturing qualifications.

 

(b)
 Prior to MTF’s supply of DBM to BBC for use with Nell-1, MTF shall have reasonably satisfied itself that MTF’s supply of
DBM to BBC for use as a carrier of Nell-1 does not violate applicable law. BBC shall provide all test results and other documentation
required or reasonably requested by MTF to assure MTF of the safety and efficacy of DBM with Nell-1 prior to distribution. All costs
and expenses related to any of the foregoing testing, retesting and development, if any, of DBM shall be borne by BBC.

 

(c)
MTF shall at its sole cost and expense obtain and maintain those manufacturing approvals and authorizations necessary to fulfill its
manufacturing and supply obligations hereunder, including without limitation, permits related to its manufacturing facility and any other
approvals required by applicable law required to manufacture, store and ship DBM.

 

(d)
In furtherance of BBC’s development activities to support the commercialization of Nell-1 with DBM, MTF shall provide reasonable
consultative support. Such consultation shall be provided at such times and places which MTF deems reasonable. MTF may make available
certain of its employees, officers and/or directors to provide consultation. Any information shared in the course of such consultation,
including internal or external to BBC development activities or internal or external to BBC in-vitro assays or in-vivo small and large
animal testing, shall be Confidential Information, as further described herein.

 

Section
3.2 Processing Standards; Packaging; Labeling. During the Term, MTF shall comply with the following standards, to the extent
applicable, in connection with the processing or manufacturing hereunder of DBM: (a) applicable laws, regulations, and guidelines of
the FDA; (b) applicable standards and guidelines promulgated by the American Association of Tissue Banks; (c) applicable laws and regulations
of other United States federal, state, and local government agencies with jurisdiction over the processing of DBM; and (d) MTF’s
standard operating procedures as they may be amended from time to time. MTF shall be responsible for determining all packaging and labeling
to be used in connection with DBM hereunder.

 

    	5

    	 

    

 

Section
3.3 Inventory and Inventory Management.

 

(a)
During the Term, MTF shall use its commercially reasonable efforts (in the context of BBC’s Forecasted Requirements) to accept
the BBC Orders in accordance with Section 2.2, and upon acceptance of a BBC Order by MTF from BBC, MTF shall use its commercially reasonable
efforts to fill the orders and deliver the filled orders of BBC Inventory to the BBC Designated Warehouse. Title to the BBC Inventory
shall vest in BBC upon delivery to the BBC Designated Warehouse (or, as applicable, delivery to the BBC customer in accordance with Section
3.3(b)), subject to BBC’s payment obligations hereunder. From the period commencing on the Effective Date and concluding on the
second anniversary thereof, no BBC Order shall indicate a delivery date for DBM that is less than one hundred twenty (120) days after
the date such BBC Order is submitted to MTF; it being further agreed that, if and to the extent BBC Orders otherwise schedule deliveries
for dates within any calendar quarter in amounts in the aggregate greater by 20% than those covered by the Forecasted Requirements for
such quarter, then MTF shall use its commercially reasonable efforts to fulfill such additional deliveries and on a date reasonably proposed
by MTF. MTF shall notify BBC upon receipt of physical inventory of DBM into the BBC Designated Warehouse. MTF shall store the BBC Inventory
in compliance with applicable laws and in a manner that permits performance of this Agreement.

 

(b)
Notwithstanding the terms of section 3.3(a), the parties agree that, in order to avoid any delay necessitated by the establishment of
the BBC Designated Warehouse and to meet BBC’s need to provide DBM to clinical sites, MTF may ship DBM directly from non-BBC Inventory
to a BBC customer. MTF may, in its discretion, fulfill a BBC Order but shall ship DBM directly to the BBC customer without the necessity
of establishing the BBC Designated Warehouse. It is the intention of the parties that the direct-ship process set forth in this section
3.3(b) shall be limited in time only to avoid delays associated with the establishment of the BBC Designated Warehouse. MTF shall notify
BBC, in writing, prior to placing any BBC Inventory in the BBC Designated Warehouse.

 

Section
3.4 Forecasts. Upon the issuance of the first marketing authorization by a Regulatory Authority to commercialize Nell-1 in
any country of the Territory and continuing during the remainder of the Term, BBC shall provide to MTF, at least thirty (30) days prior
to the first day of each calendar quarter, a good faith, non-binding written forecast of anticipated requirements for DBM (the “Forecasted
Requirements”) during the next twelve (12) calendar months, including monthly forecasted volumes. Upon the submission of
the quarterly updates to the Forecasted Requirements, BBC must submit a Purchase Order for DBM for at least the number and size of DBM
units being purchased for the following three (3) months in the Forecasted Requirements.

 

Section
3.5 Delivery. Upon acceptance of a BBC Order by MTF and subject to the terms and conditions of this Agreement, MTF shall use
its best efforts to ship the requested quantities of DBM to the BBC Designated Warehouse, or to such other destination designated by
BBC in the applicable BBC Order. Prior to delivering DBM to BBC hereunder, MTF will assess whether such DBM conforms with all applicable
specifications, and will only deliver to BBC DBM product that MTF has independently verified and confirmed complies with such applicable
specifications. Upon BBC’s request, MTF will also deliver to BBC other documentation and data corresponding to the delivered DBM
and which confirms that such delivered DBM complies with the applicable specifications. In the event that BBC determines that any delivered
DBM fails to conform to the applicable specifications (whether as a result of a latent defect or otherwise), then, BBC will provide MTF
with written notice thereof and, at MTF’s cost and expense, MTF will, within a mutually agreed upon time period, promptly replace
or reprocess such DBM so that it conforms with the applicable specifications.

 

    	6

    	 

    

 

ARTICLE
IV

REGULATORY MATTERS

 

Section
4.1 FDA Approval . MTF has received PMA clearance for DBM from FDA, a copy of which is attached hereto BBC shall be responsible
for obtaining FDA clearance of Nell-1 and the use of DBM will Nell-1. MTF shall have no obligations to obtain any clearances or other
permissions from FDA or any other agency for the use of DBM with Nell-1.

 

Section
4.2 Adverse Event Reporting and Recalls.

 

(a)
Exchange of Information. Each party shall notify the other party, within five (5) Business Days of its receipt, of any
information that it received or developed with respect to any adverse events arising from the use of DBM.

 

(b)
Reporting. BBC, at its own expense, shall be responsible for reporting to the appropriate Regulatory Authority, if necessary,
any adverse events with respect to Nell-1 with DBM, after consultation with MTF. BBC, at its own expense, shall be responsible for any
recalls of Nell-1 and agrees to indemnify, defend, and hold harmless MTF for such recalls, in accordance with Article VIII.

 

Section
4.3 Foreign Registrations; Customs Compliance. BBC, and not MTF, shall be responsible for obtaining and maintaining any DBM
product registrations which may be required for sale in those countries in the Territory outside of the United States where BBC intends
to commercialize DBM. BBC shall provide MTF with proof of such registration prior to any shipment of BBC Inventory outside of the United
States. BBC, and not MTF, shall be responsible for compliance with all United States and foreign jurisdictions’ customs compliance.

 

ARTICLE
V

OWNERSHIP OF INTELLECTUAL PROPERTY

 

Section
5.1 Intellectual Property. Notwithstanding any provision contained in this Agreement to the contrary, subject to ARTICLE VI
hereof, MTF shall retain all rights in and to the DBM IP, including its present and future Intellectual Property related to, and/or arising
out of the process used by MTF for the manufacture of the DBM. Similarly, notwithstanding any provision contained in this Agreement to
the contrary, BBC retains all rights in and to the Intellectual Property relating to Nell-1 and no rights or licenses to such Intellectual
Property are granted to MTF hereunder. In the event that MTF or BBC develops any Intellectual Property in the performance of their respective
obligations under this Agreement that constitutes an improvement to the DBM, MTF shall retain all right, title to and interest in such
improvement. Without limiting the generality of the foregoing, except as otherwise expressly set forth herein and subject solely to the
provisions of Article VI hereof: (a) each party has and shall retain exclusive ownership of, or right to use, any and all right and title
to and interest in such party’s Intellectual Property, regulatory approvals and other proprietary rights, and (b) none of the parties
has acquired, nor shall it acquire by virtue of this Agreement or the activities contemplated hereby, any interest in or license under
or right to use any of the other parties’ Intellectual Property, regulatory approvals and other proprietary rights existing as
of the date hereof or thereafter.

 

    	7

    	 

    

 

ARTICLE
VI

LICENSE
GRANTS; AUDIT RIGHTS

 

Section
6.1 License Grants.

 

(a)
By MTF. MTF hereby grants to BBC a fully-paid, royalty-free, non-exclusive license within the Territory, under all DBM
IP and any copyrights approved for use by MTF in any MTF marketing or product materials, solely for the purpose of conducting the activities
relating to the marketing, promotion and sales of DBM in the Territory for use in the Field pursuant to the provisions of this Agreement.
Any such DBM IP, trademarks, service marks and copyrights utilized by BBC as aforesaid shall in each instance indicate that they belong
to MTF, and BBC shall comply with all notice and marking requirements, and all additional written standards of quality control, all as
communicated to BBC and required by MTF for the protection and enforcement of such trademarks, service marks and copyrights and the registration
thereof and shall not utilize any such trademarks, service marks and copyrights in any manner which might dilute or tarnish them or reflect
adversely on MTF. Without limiting the generality of the foregoing, BBC shall not in any manner modify any trademark, service mark or
copyright licensed by MTF hereunder, or utilize any variant thereof, singly or in combination with any other term or material, without
the prior written consent of MTF having been obtained in each case.

 

Section
6.2 Term of License. The licenses granted hereunder shall continue for so long as the Term remains in full force and effect.

 

Section
6.3 Right to Audit BBC Books and Records. BBC shall keep complete and accurate books and records containing information which
may be necessary to ascertain and verify compliance under any laws, rules or regulations regarding its marketing, sale and distribution
of the DBM. Such books and records shall be open to examination by MTF during normal business hours upon reasonable prior notice. MTF
may exercise its right of audit from time to time consistent with its standard operating procedures with respect to regulatory compliance.
All information, documents and records of BBC acquired in the course of such audit shall be treated as Confidential Information in accordance
with Article VII below. The records for any given calendar year shall be preserved for a period of three (3) years from the end of that
calendar year or such longer period as required by law.

 

ARTICLE
VII

CONFIDENTIAL INFORMATION

 

Section
7.1 Confidential Information. Except as expressly provided herein, BBC and MTF agree that from the Effective Date of this
Agreement, neither shall publish or otherwise disclose, nor shall either use for any purpose not contemplated herein, any Confidential
Information furnished to it by the other party hereto pursuant to this Agreement; provided, however, that BBC and MTF may disclose any
such Confidential Information of the other party to those of their respective directors, officers, agents, advisors, employees and consultants
who need to know such Confidential Information in furtherance of the purpose contemplated herein and who are obligated in writing to
maintain the confidential nature of such Confidential Information on terms not less restrictive than those set forth in this Agreement.
Disclosure of Confidential Information shall be only for furtherance of this and shall be to Jeff Frelick on the part of BBC.

 

    	8

    	 

    

 

Each
party shall use its best efforts to ensure that any Confidential Information diclosed in tangible form shall be marked “Confidential”
or with other similar designation to indicate its confidential or proprietary nature; provided, however, that a party’s failure
to mark as “Confidential” or with other similar designation to indicate the confidential or proprietary nature of the information
disclosed shall not designate the information contained therein as being non-Confidential Information. Any Confidential Information disclosed
orally shall be confirmed as confidential or proprietary by the party disclosing such information within thirty (30) days of such disclosure.
For purposes of this Agreement, “Confidential Information” shall mean information which is disclosed by a party
to this Agreement to the other party; provided, however, that notwithstanding the foregoing, it is understood and agreed that Confidential
Information shall not include information that, in each case as demonstrated by written documentation, (a) was already known to the receiving
party, other than under an obligation of confidentiality, at the time of disclosure; (b) was generally available to the public or otherwise
part of the public domain at the time of its disclosure to the receiving party; (c) became generally available to the public or otherwise
part of the public domain after its disclosure other than through any act or omission of the receiving party in breach of this Agreement;
(d) was subsequently lawfully disclosed to the receiving party by a person other than a party hereto; or (e) is independently developed
by the receiving party without reference to any information or materials disclosed by the disclosing party, as evidenced by the receiving
party’s relevant documentation; or (f) is disclosed generally to a third party without restrictions similar to those contained
in this Agreement.

 

Section
7.2 Permitted Disclosures. Notwithstanding the provisions of Section 7.1. above, each party hereto may disclose the other’s
Confidential Information, to the extent such disclosure is reasonably necessary in complying with applicable court or governmental orders,
or governmental regulations, submitting information to tax or other governmental authorities; provided that (a) if a party is legally
required to make any such disclosure of the other party’s Confidential Information, to the extent it may legally do so, it will
give reasonable advance written notice to the other party of such anticipated disclosure and, will use its reasonable best efforts to
secure confidential treatment of such Confidential Information prior to its disclosure (whether through protective orders or otherwise),
and (b) with respect to BBC and MTF’s marketing activities, it is agreed that no disclosure may occur until after having provided
the disclosing party a reasonable opportunity to (i) prepare and file patent applications covering inventions describe in such Confidential
Information have been filed, or (ii) seek adequate protection to maintain the patentability of inventions described in such Confidential
Information, or (iii) adequate protection has been obtained to maintain the secrecy of such Confidential Information.

 

    	9

    	 

    

 

ARTICLE
VIII

INDEMNIFICATION

 

Section
8.1 Negligence, Willful Misconduct. MTF agrees to hold harmless, defend, and indemnify BBC and its affiliates, representatives,
officers, directors, employees, shareholders and agents against all damages, claims, actions, suits, liabilities, judgments and awards,
including reasonable attorneys’ fees (collectively “Damages”) sustained or incurred as a result of or
in connection with (a) any breach by MTF of any warranty made herein or related to DBM, or any breach of MTF’s obligations under
this Agreement, and (b) MTF’s negligent performance of its designated activities under this Agreement including, without limitation,
its activities relating to the manufacture and supply of DBM, except to the extent caused by (i) BBC’s advertising or promotional
material for DBM not approved or otherwise authorized by MTF, (ii) any unauthorized use by BBC of DBM, or (iii) BBC’s sales activities
or breach of its obligations under this Agreement. Notwithstanding the foregoing, each party shall hold harmless, defend and indemnify
the other, from and against any Damages arising out of or relating to bodily injury or death of any person or damage to real and/or tangible
personal property directly caused by the negligence or willful misconduct of the indemnifying party or its personnel in connection with
the performance of this Agreement.

 

Section
8.2 Intellectual Property Indemnification of BBC. MTF agrees to hold harmless, defend, and indemnify BBC and its affiliates,
representatives, officers, directors, employees, shareholders and agents against all Damages sustained or incurred as a result of any
third party claims alleging that DBM, or the use, commercialization or sale thereof infringes such third party’s Intellectual Property
rights. BBC shall promptly notify MTF in writing of a third party claim against BBC alleging that DBM infringes a third party’s
Intellectual Property rights, and MTF shall defend such claim at its expense and shall pay any Damages that may be finally awarded against
BBC. If DBM is, or in MTF’s opinion is likely to be, held to be infringing or defective, MTF may terminate this Agreement upon
providing BBC notice thereof; provided, however, that such a termination shall not relieve MTF of its obligation to indemnify BBC in
accordance with this Article VIII.

 

Section
8.3 Indemnification of MTF. BBC shall hold harmless, defend and indemnify MTF, its affiliates, representatives, officers,
directors, employees, shareholders and agents from and against any Damages sustained or incurred as a result of or in connection with
(i) any third party claims alleging that Nell-1or Nell-1 with DBM, or the use, commercialization or sale thereof infringes such third
party’s Intellectual Property rights; or (ii) BBC’s negligent performance of its designated activities under this Agreement
including, without limitation, its activities relating to the promotion, marketing, sales and solicitation of orders of Nell-1 or Nell-1
with DBM, and the activities of any third party acting on BBC’s behalf for the promotion, marketing, sales and solicitation of
orders of Nell-1 or Nell-1 with DBM; in each case, only to the extent that such third party claim is not subject to MTF’s obligation
to indemnify BBC as set forth in Sections 8.1 and 8.2.

 

Section
8.4 Notice and Cooperation. To receive the foregoing indemnities, the party seeking indemnification must promptly notify the
other in writing of a claim or suit and provide reasonable cooperation (at the indemnifying party’s expense) and full authority
to defend or settle the claim or suit (provided that failure to give any such notice shall not affect indemnification hereunder except
to the extent the indemnifying party is prejudiced as a result of such failure). The indemnifying party shall have no obligation to indemnify
the indemnified party under any settlement made without the indemnifying party’s written consent.

 

    	10

    	 

    

 

ARTICLE
IX

TERM AND TERMINATION

 

Section
9.1 Term. This Agreement shall become effective on the Effective Date and shall remain in effect for a period of Five Years
following the date of BBC’s first placement to of a BBC Order (the “Initial Term”), unless earlier terminated
at any time upon the mutual written consent of BBC and MTF or otherwise terminated in accordance with the provisions of this Article
IX.

 

Section
9.2 Renewal. The Initial Term of this Agreement may be extended for one (1) or more years (“Renewal Periods”)
upon mutual agreement of BBC and MTF. BBC and MTF agree to initiate negotiation Renewal Periods at least ninety (90) days prior to the
expiration of the Initial Term and any subsequent Renewal Period regarding such renewal.

 

Section
9.3 Default. If a party defaults in the performance of any of its material obligations hereunder, the non-defaulting party
shall provide the defaulting party with written notice of the default. If, within thirty (30) days after such written notice, the default
has not been cured, the non-defaulting party, at its option, may terminate this Agreement by giving written notice of termination to
the defaulting party.

 

Section
9.4 Termination for Change in Control. Notwithstanding the provisions of Section 9.5 below, either MTF or BBC may terminate
this Agreement on six (6) months’ prior written notice to the other party hereto if such other party is subject to a Change-in-Control
to which such other party withheld its consent in accordance with Section 12.11, and such notice is given to the terminated party within
thirty (30) days after such Change-in-Control. For purposes of this Section 9.4, “Change-in-Control” shall
mean a transaction or series of transactions in which the shareholders or owners of the subject entity immediately prior to such transaction
or series of transactions own immediately after such transaction or series of transactions, directly or indirectly, less than fifty percent
(50%) of the outstanding voting securities or other ownership interest of the surviving entity (or its parent), or a sale of all or substantially
all of the assets of the subject entity. Each party shall deliver prompt written notice to the other party in the event of any Change-in-Control.
For the avoidance of doubt, MTF and BBC shall have no right to terminate this Agreement pursuant to this Section 9.4 in the event that
such party consented to the Change-in-Control of the other party in accordance with Section 12.11.

 

Section
9.4 Bankruptcy; Dissolution; Etc. Either party hereto may terminate this Agreement immediately by written notice to the other
party, if (i) such other party shall make an assignment of substantially all of its assets for the benefit of creditors, file a petition
in bankruptcy, petition or apply to any tribunal for the appointment of a custodian, receiver or any trustee for such party of all or
substantially all of such party’s assets, or shall commence any proceeding under any dissolution or liquidation law or statute
of any jurisdiction, whether now or hereafter in effect; or (ii) there shall have been filed any such petition or application against
such other party, or any such proceeding shall have been commenced against such party, in which an order for relief is entered or which
remains un-dismissed for a period of sixty (60) days or more, or (iii) such other party, by an act or knowing failure to act, shall indicate
such party’s consent to, approval of or acquiescence in, any such petition, application or proceeding, or order for relief, or
the appointment of a custodian, receiver or any trustee for such party, of all or any substantial part of any of such party’s properties,
or (iv) such party shall be liquidated or dissolved.

 

    	11

    	 

    

 

Section
9.5 Termination for Non-Performance.

 

(a)
Termination by MTF. MTF may terminate this Agreement for non-performance by providing prior written notice to BBC, if BBC
fails to purchase DBM which equal at least seventy-five percent (75%) of the Forecasted Requirements in any two (2) consecutive Term
Years except in that instance where the shortfall results from MTF’s failure to manufacture DBM in quantities sufficient to meet
the Forecasted Requirements and except that MTF’s notice of termination shall not become effective if, within thirty (30) days
of the receipt of such notice, BBC shall place additional BBC Orders with MTF requiring purchase of additional DBM as shall, when purchased,
at least equal such deficiency (no such purchases to enter into calculation of achievement of the Forecasted Requirements for the then
current Term Year or any subsequent Term Year).

 

(b)
Termination by BBC. BBC may terminate this Agreement for non-performance by providing written notice to MTF, if MTF fails
to produce DBM which equal at least seventy-five percent (75%) of the Forecasted Requirements subject to BBC Orders in any two (2) consecutive
Term Years except in that instance where the shortfall results from BBC’s failure to order DBM in quantities sufficient to meet
the Forecasted Requirements.

 

Section
9.6 Effect of Termination

 

(a)
Accrued Obligations Termination of this Agreement for any reason shall not release any party hereto from any liability
which, at the time of such termination, has already accrued to the other party or which is attributable to a period prior to the effective
date of such termination, or preclude either party from pursuing all rights and remedies it may have hereunder or at law or in equity
with respect to any breach of this Agreement.

 

(b)
Return of Materials. All Confidential Information shall remain the sole property of the disclosing party. Within thirty
(30) days after a disclosing party’s request therefor, each receiving party shall destroy all Confidential Information of the other
party in its possession or control and provide written certification to the other party within ten (10) Business Days of such destruction,
or prepare such Confidential Information for shipment to such other party, as the other party may direct, at the other party’s
expense. Promptly after expiration or termination of this Agreement, but in any event within thirty (30) days, MTF shall have the right,
at its sole discretion, to repurchase the remaining BBC Inventory, if any, from BBC at the applicable MTF Service Fee prices set forth
on Exhibit B.

 

Section
9.7 Survival. Except as otherwise expressly provided herein, the parties’ rights and obligations pursuant to Sections
6.3, 9.7, and Articles IV, V, VII, VIII, and X, XI and XII of this Agreement shall survive any expiration or earlier termination of this
Agreement.

 

ARTICLE
X

REPRESENTATIONS AND WARRANTIES

 

Section
10.1 By MTF. MTF warrants and represents to BBC on the date of this Agreement that (i) it is a non-profit corporation duly
organized, validly existing and in good standing under the laws of the District of Columbia and it has the full right and authority to
enter into this Agreement and grant the rights granted herein, (ii) except as otherwise permitted under this Agreement, it has not previously
granted and will not grant any rights in conflict with the rights granted herein, (iii) to its knowledge and belief, there are no threatened
or pending actions, suits or claims against it with respect to or relating in any way to its right to enter into and perform its obligations
under this Agreement, (iv) DBM is, and upon delivery to BBC or to the BBC Designated Warehouse will comply with all applicable specifications
and will be, free from defects, shall not be adulterated or misbranded within the meaning of the Federal Food Drug and Cosmetic Act,
and is manufactured in a manner that meets or exceeds reasonable manufacturing standards for such products, including all FDA standards
and regulations concerning such products and will strictly conform to the applicable published Specifications, and (v) DBM and the manufacture,
use, promotion, and sale thereof in accordance with this Agreement do not and, to the best of MTF’s knowledge, will not infringe
third party Intellectual Property rights.

 

    	12

    	 

    

 

Section
10.2 By BBC. BBC warrants and represents to MTF on the date of this Agreement that (i) it is a corporation duly organized,
validly existing and in good standing under the laws of its jurisdiction of incorporation and it has the full right and authority to
enter into this Agreement and perform its obligations set forth herein, (ii) it has not previously granted and will not grant any rights
in conflict with its obligations under this Agreement, and (iii) to its knowledge and belief, there are no threatened or pending actions,
suits or claims with respect to or relating in any way to its right to enter into and perform its obligations under this Agreement.

 

Section
10.3 Disclaimer of Warranties. NEITHER PARTY MAKES ANY REPRESENTATIONS OR WARRANTIES, OTHER THAN THE REPRESENTATIONS AND WARRANTIES
EXPRESSLY MADE IN THIS AGREEMENT, AND EACH PARTY SPECIFICALLY DISCLAIMS ANY AND ALL WARRANTIES, EXPRESS OR IMPLIED.

 

ARTICLE
XI

LIMITATION OF LIABILITY

 

WITH
THE EXCEPTION OF DAMAGES ARISING AS A RESULT OF A PARTY’S BREACH OF ARTICLE VII, A PARTY’S GROSS NEGLIGENCE OR INTENTIONAL
MISCONDUCT, OR A PARTY’S FAILURE TO INDEMNIFY THE OTHER PARTY IN ACCORDANCE WITH ARTICLE VIII, IN NO EVENT SHALL ANY PARTY OR ANY
OF ITS SUPPLIERS OR AGENTS BE LIABLE FOR LOSS OF PROFIT, GOODWILL OR OTHER CONSEQUENTIAL OR INCIDENTAL DAMAGES ARISING OUT OF THIS AGREEMENT
EVEN IF SUCH PARTY IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.

 

ARTICLE
XII

MISCELLANEOUS

 

Section
12.1 Governing Law. This Agreement shall be governed by, and construed and enforced in accordance with, the laws of the State
of New Jersey, without regard to conflict of law principles.

 

Section
12.2 Independent Contractors. It is understood that each party is an independent contractor, that no activities under this
Agreement shall create or be deemed to create any agency relationship between the parties, and that persons engaged in work by one party
hereunder shall not in any sense be considered as employees of the other. Without limiting the generality of the foregoing, but without
abridging MTF’s express obligations under this Agreement, in no event shall MTF be liable for or obligated under the terms and
provisions of any customer fulfillment order or any other terms or conditions of sale to any fulfillment customer prescribed or agreed
to by BBC which terms, provisions or conditions are not expressly agreed to by MTF in advance and in writing or in this Agreement.

 

    	13

    	 

    

 

Section
12.3 Expenses. Except as expressly stated herein, each of the parties hereto shall bear and pay such party’s own costs
and expenses incurred in connection with the negotiation, preparation, execution, delivery, and performance of this Agreement and the
transactions contemplated hereby.

 

Section
12.4 Press Releases and Other Publicity Announcements. Any public announcement or similar publicity with respect to this Agreement
shall be subject to the prior consent of the non-publishing party, which consent shall not be unreasonably withheld, unless such communication
is required to be made by law.

 

Section
12.5 Entire Agreement and Binding Effect; Survival of Representations. This Agreement and the Exhibits hereto constitute the
entire agreement between the parties with respect to the subject matter hereof, and supersede all prior understandings, arrangements,
and agreements with respect to the subject matter hereof. Subject to the provisions of this Agreement relating to transferability, this
Agreement shall be binding upon and shall inure to the benefit of the parties, and their respective successors and assigns. No modification
hereof shall be effective unless in writing and signed by the party against which it is sought to be enforced.

 

Section
12.6 No Waiver. Any failure of a party to require the other party to comply with any provisions of this Agreement shall not
be deemed a waiver of such provision or any other provision of this Agreement.

 

Section
12.7 Severability. The invalidity or unenforceability of any particular provision of this Agreement shall not affect the other
provisions hereof, and this Agreement shall be construed in all respects as if such invalid or unenforceable provision were omitted and
in a manner to most closely accomplish the intent of the parties.

 

Section
12.8 Headings. The section headings contained in this Agreement have been inserted only as a matter of convenience and for
reference, and in no way shall be construed to define, limit or describe the scope or intent of any provision of this Agreement.

 

Section
12.9 Counterparts. This Agreement may be executed in multiple counterparts, each of which will be deemed an original, but
all of which shall constitute one and the same.

 

Section
12.10 Amendments. This Agreement may only be amended by a written amendment executed by BBC and MTF.

 

Section
12.11 Assignment. Neither party may assign this Agreement or any of its rights, obligations or privileges hereunder, whether
by way of a Change-in-Control or otherwise, without the prior written consent of the other party, which consent shall not be unreasonably
withheld or delayed. Any such impermissible assignment shall be void.

 

Section
12.12 Notices. Any and all notices, demands and other communications required or permitted under this Agreement shall be deemed
adequately given upon receipt, only if in writing and if the same shall be delivered by hand, by mail or by Federal Express or similar
expedited commercial carrier, addressed to the recipient of the notice, postage prepaid and registered or certified with return receipt
requested (if by mail), or with air freight charges prepaid (if by Federal Express or similar carrier). All such notices, demands and
other communications shall be addressed as set forth on the Notices Schedule attached hereto as Exhibit D or to such other
address as any party may have designated for itself by written notice to the other party in the manner herein prescribed.

 

    	14

    	 

    

 

Section
12.13 Force Majeure. Notwithstanding anything contained in this Agreement to the contrary, no default, delay or failure to
perform on the part of either party shall be considered a breach of this Agreement if such default, delay or failure to perform is shown
to be due to causes beyond the reasonable control of the party charged with a default (“Force Majeure”), including,
but not limited to, causes such as strikes, lockouts or other labor disputes, actions or inactions of governmental authorities or suppliers,
embargoes, severe weather, fire and other acts of God, or default of a common carrier or; provided, however, that, in the event of either
party being rendered unable by a Force Majeure to carry out its obligations under this Agreement, such party shall give notice and full
particulars, including the expected duration of such Force Majeure, in writing to the other party not later than three (3)days after
the occurrence of the cause of the Force Majeure and upon the cessation of the cause of such Force Majeure, shall resume performance.

 

Section
12.14 Dispute Resolution; Jurisdiction and Venue. Upon the occurrence of a dispute among the parties, including, without limitation,
any breach of this Agreement or any obligation relating thereto, the matter shall be referred to the general managers of MTF and BBC,
or their designees. The general managers, or their designees, as the case may be, shall negotiate in good faith to resolve such dispute
in a mutually satisfactory manner for thirty (30) days, or such longer period of time to which the general managers may agree. After
such thirty (30)-day period, the parties agree that the courts of the State of New Jersey shall have non-exclusive jurisdiction over
any action for enforcement or interpretation of this Agreement or for damages for the violation of any of the provisions hereof, and
that venue shall be proper for such an action in any court located in or having jurisdiction over the State of New Jersey. This Section
12.14 shall not preclude either party from seeking injunctive relief from a court of competent jurisdiction to protect its interests.

 

Section
12.15 Insurance. Commencing on the date of each party’s first commercial sale of DBM hereunder, BBC and MTF shall obtain
and maintain product liability insurance or its equivalent and such other insurance coverages as are customarily maintained by parties
engaged in similar businesses (including, without limitation, property insurance covering the BBC Inventory), in each case, in amounts
commercially reasonable and sufficient in view of the activities contemplated pursuant to this Agreement. MTF shall arrange for BBC to
be a named insured on its product liability insurance policy and shall furnish a certificate of insurance to BBC within thirty (30) days
of the Effective Date.

 

Section
12.16 Injunctive Relief. BBC and MTF acknowledge and agree that their respective agreements are of a special unique and extraordinary
nature and that the non-breaching party would suffer irreparable injury as a consequence of violation thereof, and by reason thereof
each party consents and agrees that, if it should in any way violate such provisions, the other party shall be entitled to injunctive
relief issued by any court of competent jurisdiction restraining the violator from committing or continuing any such violation.

 

[This
space intentionally left blank.]

 

    	15

    	 

    

 

IN
WITNESS WHEREOF, the parties have executed and delivered this Agreement as of the date first set forth above.

 

	BONE BIOLOGICS CORPORATION	 	MUSCULOSKELETAL TRANSPLANT FOUNDATION, INC.
	 	 	 	 	 
	By:	                   
	 	By:	                            

    

	Name:	 	 	Name:	 
	Title:	 	 	Title:	 
	Date:	 	 	Date:	 

 

    	16

    	 

    

 

EXHIBIT
A

 

DBMPMA
Clearances

 

    	17

    	 

    

 

EXHIBIT
B

 

MTF SERVICE FEES
 

    	18

    	 

    

 

EXHIBIT
C

 

MTF
RETURN POLICY

 

Due
to the unique nature of donated tissues and the preservation techniques used, the following policies refer to DBM:

 

DBM
may be returned for credit in the following instances without a restocking fee:

 

	 	●	It
    does not meet MTF published specifications
	 	 	 
	 	 	Note:
    Claims of unsatisfactory specifications must be reported to MTF within 30 days of the date of invoice to be eligible for return.
    Please be prepared to provide the tissue code and serial number along with a description of the adverse event.
	 	 	 
	 	●	DBM
    or packaging is damaged in shipment
	 	 	 
	 	 	Note:
    Claims for damaged tissue packages must be reported to MTF within five days of receipt of tissue to be eligible for credit.
	 	 	 
	 	●	Order
    discrepancies
	 	 	 
	 	 	Note:
    Claims for order discrepancies must be reported to BBC within five days of receipt of tissue to be eligible for credit.

 

Address
for Returns

Musculoskeletal
Transplant Foundation (MTF)

1175
Midvalley Drive

Olyphant,
PA 18447

 

    	19

    	 

    

 

EXHIBIT
D

 

NOTICES

 

To
MTF:

 

125
May Street, Suite 200

Edison,
New Jersey 08837

Attention:
President and CEO

 

To
BBC:

 

2
Burlington Woods Drive, Suite 100

Burlington,
Massachusetts 01803

Attention:
President and CEO

 

    	20

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00342-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00342-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00342-of-00352.parquet"}]]